Vis enkel innførsel

dc.contributor.authorHoffmann-Vold, Anna-Maria
dc.contributor.authorFretheim, Håvard Halland
dc.contributor.authorSarna, Vikas Kumar
dc.contributor.authorBarua, Imon Shoumitra
dc.contributor.authorCarstens, Maylen N.
dc.contributor.authorDistler, Oliver
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorVolkmann, Elizabeth R.
dc.contributor.authorMidtvedt, Øyvind
dc.contributor.authorDidriksen, Henriette
dc.contributor.authorDhainaut, Alvilde
dc.contributor.authorHalse, Anne Kristine Hjorteseth
dc.contributor.authorBakland, Gunnstein
dc.contributor.authorPesonen, Maiju
dc.contributor.authorOlsen, Inge Christoffer
dc.contributor.authorMolberg, Øyvind
dc.date.accessioned2021-09-29T11:23:18Z
dc.date.available2021-09-29T11:23:18Z
dc.date.created2021-08-06T15:20:24Z
dc.date.issued2021
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/11250/2786003
dc.description.abstractIntroduction: In the multisystem inflammatory disorder systemic sclerosis (SSc), gastrointestinal tract (GIT) affliction is highly prevalent. There are no known disease modifying therapies and the negative impact is substantial. Aiming for a new therapeutic principle, and inspired by recent work showing associations between gut microbiota changes and GIT symptoms in SSc, we performed a pilot study on faecal microbiota transplantation (FMT) with the single-donor bacterial culture ‘Anaerobic Cultivated Human Intestinal Microbiome (ACHIM)’. Motivated by positive pilot study signals, we designed the ReSScue trial as a phase II multicentre, placebo-controlled, randomised 20-week trial to evaluate safety and efficacy on lower GIT symptoms of FMT by ACHIM in SSc. Methods and analyses: We aim to include 70 SSc participants with moderate to severe lower GIT symptoms, defined by the validated patient-reported University of California Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 2.0 questionnaire. The trial includes three parts. In part A1 (induction phase) lasting from week 0 to week 12, participants will be randomised 1:1 to repeat infusions of 30 mL ACHIM or placebo at week 0 and 2 by gastroduodenoscopy. In part A2, which is an 8-week subsequent maintenance phase, all study participants will receive 30 mL ACHIM at week 12 and followed until week 20 on continued blind. In part B, which will last until the last participant completes part A2, the participants will be followed through a maximum 16-week extended monitoring period, for longer-term data on safety and intervention effects. Primary endpoint is change from baseline to week 12 in UCLA GIT subscale scores of diarrhoea or bloating, depending on the worst symptom at baseline evaluated separately for each patient. Secondary endpoints are safety measures and changes in UCLA GIT scores (total, diarrhoea and bloating).en_US
dc.language.isoengen_US
dc.publisherBMJen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSafety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: Study protocol for the randomised controlled phase II ReSScue trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 the authorsen_US
dc.source.articlenumbere048541en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1136/bmjopen-2020-048541
dc.identifier.cristin1924447
dc.source.journalBMJ Openen_US
dc.identifier.citationBMJ Open. 2021, 11 (6), e048541.en_US
dc.source.volume11en_US
dc.source.issue6en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal